Microba Life Sciences Ltd has released a press release.
Q1 FY24 Quarterly Activities Report & Appendix 4C
Filed with ASX ·
Watch Microba Life Sciences' latest callMicroba Life Sciences (ASX:MAP) Q4 2025 Earnings Call · Replay · Jul 22, 2025Read the transcript of Microba Life Sciences (ASX:MAP) Q4 2025 Earnings Call6ix hasn’t read this filing yet.
Microba Life Sciences Limited on 6ix
In the deck
Story so far
Earlier from Microba Life Sciences
- Appendix 4E & Annual Report
- Q4 FY23 Quarterly Investor Presentation
- Q4 FY23 Quarterly Activities Report & Appendix 4C
- First Distribution Agreement Executed with Sonic Healthcare
- Microba Commences Phase I Clinical Trial for IBD Therapeutic
Later from Microba Life Sciences
- Microba to acquire UK microbiome leader Invivo Clinical
- Invivo Clinical Acquisition and Capital Raising Presentation
- Fully Underwritten A$20 million Entitlement Offer
- Results of Retail Entitlement Offer
- Autoimmune Stage 1 Screening Complete with Gingko Bioworks
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences